The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Efficacy and Safety of Ocrelizumab in Active Proliferative Lupus Nephritis: Results From a Randomized, Double‐Blind, Phase III Study
Open accessAbstract
Objective: To investigate the efficacy and safety of ocrelizumab in patients with class III/IV lupus nephritis (LN). Methods: Patients were randomized 1:1:1 to receive placebo, 400 mg ocrelizumab, or 1,000 mg ocrelizumab given as an intravenous infusion on days 1 and 15, followed by a single infusion at week 16 and every 16 weeks thereafter, accompanied by background glucocorticoids plus either mycophenolate mofetil (MMF) or the Euro‐Lupus Nephritis Trial (ELNT) regimen (cyclophosphamide followed by azathioprine). The study was terminated early due to an imbalance in serious infections in ocrelizumab‐treated patients versus placebo‐treated patients. We report week 48 efficacy data for patients receiving ≥32 weeks of treatment (n = 223) and safety results for all treated patients (n = 378). Results: The overall renal response rate was 54.7%, 66.7%, 67.1%, and 66.9% in the placebo‐treated, 400 mg ocrelizumab–treated, 1,000 mg ocrelizumab–treated, and combined ocrelizumab‐treated groups, respectively. The associated treatment difference versus placebo for the combined ocrelizumab‐treated groups was 12.7% (95% confidence interval [95% CI] −0.8, 26.1) (P = 0.065), with similar differences observed for both ocrelizumab‐treated groups. Ocrelizumab versus placebo treatment differences were apparent in patients receiving the background ELNT regimen, but not in those receiving background MMF. A numerically greater proportion of ocrelizumab‐treated patients had a ≥50% reduction in the urinary protein:urinary creatinine ratio at 48 weeks compared with placebo‐treated patients (placebo‐treated patients, 58.7%; 400 mg ocrelizumab–treated patients, 70.7%; 1,000 mg ocrelizumab–treated patients, 68.5%). Serious adverse events occurred in 27.2% of placebo‐treated patients, 35.7% of 400 mg ocrelizumab–treated patients, and 22.0% of 1,000 mg ocrelizumab–treated patients. Corresponding serious infection rates (events/100 patient‐years) were 18.7 (95% CI 12.2, 28.7), 28.8 (95% CI 20.6, 40.3), and 25.1 (95% CI 17.4, 36.1), respectively. The imbalance in serious infections with ocrelizumab occurred with background MMF but not with the background ELNT regimen. Conclusion: In patients with active LN, overall renal response rates with ocrelizumab were numerically but not statistically significantly superior to those with placebo. Ocrelizumab treatment was associated with a higher rate of serious infections in the subgroup receiving background MMF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manson, J. J., Ma, A., Rogers, P., Mason, L. J., Berden, J. H., van der Vlag, J., D'Cruz, D. P., Isenberg, D. A., & Rahman, A. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2831 · Cited by 129
Cited by
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,518
Self-citationAnders, H.-J., Saxena, R., Zhao, M.-H., Parodis, I., Salmon, J. E., & Mohan, C. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0141-9 · Cited by 958
KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS
Rovin, B. H., Ayoub, I. M., Chan, T. M., Liu, Z.-H., Mejía-Vilet, J. M., & Floege, J. (2024) · Kidney International · doi:10.1016/j.kint.2023.09.002 · Cited by 517
Hoffman, W., Lakkis, F. G., & Chalasani, G. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09430915 · Cited by 482
Furie, R. A., Aroca, G., Cascino, M. D., Garg, J. P., Rovin, B. H., Alvarez, A., Fragoso-Loyo, H., Zuta-Santillan, E., Schindler, T., Brunetta, P., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-220920 · Cited by 459
Self-citation
Metadata
- Authors
- Mysler, E. F., Spindler, A. J., Guzman, R., Bijl, M., Jayne, D., Furie, R. A., Houssiau, F. A., Drappa, J., Close, D., Maciuca, R., Rao, K., Shahdad, S., & Brunetta, P.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2013-08-26
- Volume
- 65
- Issue
- 9
- Pages
- 2368-2379
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W1688265474
- Cited by
- 353
- References
- 1
- FWCI
- 22.05
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and Safety of Ocrelizumab in Active Proliferative Lupus Nephritis: Results From a Randomized, Double‐Blind, Phase III Study. https://app.cochat.ai/papers/10.1002/art.38037
- The paper
- Mysler, E. F., Spindler, A. J., Guzman, R., Bijl, M., Jayne, D., Furie, R. A., Houssiau, F. A., Drappa, J., Close, D., Maciuca, R., Rao, K., Shahdad, S., & Brunetta, P. (2013). Efficacy and Safety of Ocrelizumab in Active Proliferative Lupus Nephritis: Results From a Randomized, Double‐Blind, Phase III Study. Arthritis & Rheumatism. https://doi.org/10.1002/art.38037
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.